Publications by authors named "Thomas A Ciulla"

Claim this Profile
B
Beyond the injection: delivery systems reshaping retinal disease management.
Lucas W Rowe, Christian Akotoye, Alon Harris, Thomas A Ciulla

Expert Opin Pharmacother· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autoimmune neuro-ophthalmic disorders: pathophysiologic mechanisms and targeted biologic therapies.
Lucas W Rowe, Zachary R Barry, Devin D Mackay, Kevin E Lai, Thomas A Ciulla

Expert Opin Biol Ther· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spectral-domain OCT characteristics of intraretinal hyper-reflective foci associated with age-related macular degeneration and diabetic retinopathy.
Maryam Ashrafkhorasani, Abbas Habibi, Muneeswar Gupta Nittala, Mehdi Yaseri, Mehdi Emamverdi, Thomas A Ciulla

Can J Ophthalmol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
THREE-YEAR CLINICAL OUTCOMES IN GEOGRAPHIC ATROPHY: An Analysis of 18,712 Patient Eyes.
Aumer Shughoury, Nick Boucher, Nitika Aggarwal, Thomas A Ciulla

Retina· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suprachoroidal drug delivery: a versatile therapeutic platform.
Thomas A Ciulla, Emmett T Cunningham

Expert Opin Drug Deliv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of CLS-TA by Anatomic Location of Inflammation: Results from the Phase 3 PEACHTREE Clinical Trial.
Milan Shah, Thomas Albini, Quan Nguyen, Charles Wykoff, Mark Barakat, Thomas A Ciulla

Ocul Immunol Inflamm· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-acting delivery and therapies for neovascular age-related macular degeneration.
Lucas W Rowe, Thomas A Ciulla

Expert Opin Biol Ther· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SUPRACHOROIDAL SPACE INJECTION TECHNIQUE: Expert Panel Guidance.
Charles C Wykoff, Robert L Avery, Mark R Barakat, David S Boyer, David M Brown, Thomas A Ciulla

Retina· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene Therapy for Non-Hereditary Retinal Disease: Age-Related Macular Degeneration, Diabetic Retinopathy, and Beyond.
Lucas W Rowe, Thomas A Ciulla

Genes (Basel)· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OCT outcomes as biomarkers for disease status, visual function, and prognosis in diabetic macular edema.
Swetha Bindu Velaga, Muneeswar Gupta Nittala, Ahmed Roshdy Alagorie, Jyotsna Marram, Zhihong Jewel Hu, Thomas A Ciulla

Can J Ophthalmol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suprachoroidal Drug Delivery for Macular Edema Associated With Noninfectious Uveitis.
Ye Huang, Charlene Choo, Shelley Hancock, Thomas A Ciulla, Charles C Wykoff

J Vitreoretin Dis· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evolving therapeutic landscape of diabetic retinopathy.
Aumer Shughoury, Ashay Bhatwadekar, Denis Jusufbegovic, Amir Hajrasouliha, Thomas A Ciulla

Expert Opin Biol Ther· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The complement system: a novel therapeutic target for age-related macular degeneration.
Aumer Shughoury, Duriye D Sevgi, Thomas A Ciulla

Expert Opin Pharmacother· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triamcinolone Acetonide Suprachoroidal Injectable Suspension for Uveitic Macular Edema: Integrated Analysis of Two Phase 3 Studies.
Steven Yeh, Christopher R Henry, Barry Kapik, Thomas A Ciulla

Ophthalmol Ther· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications.
Aditya Belamkar, Alon Harris, Ryan Zukerman, Brent Siesky, Francesco Oddone, Thomas A Ciulla

Ann Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anatomic Biomarkers of Macular Edema Associated with Retinal Vein Occlusion.
Thomas A Ciulla, Barry Kapik, Allen Hu, Alon Harris, Michael S Ip

Ophthalmol Retina· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longer-Term Anti-VEGF Therapy Outcomes in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Vein Occlusion-Related Macular Edema: Clinical Outcomes in 130 247 Eyes.
Thomas A Ciulla, Rehan M Hussain, Donna Taraborelli, John S Pollack, David F Williams

Ophthalmol Retina· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suprachoroidal delivery enables targeting, localization and durability of small molecule suspensions.
Viral S Kansara, Shelley E Hancock, Leroy W Muya, Thomas A Ciulla

J Control Release· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancements in ocular gene therapy delivery: vectors and subretinal, intravitreal, and suprachoroidal techniques.
Kyle D Kovacs, Thomas A Ciulla, Szilárd Kiss

Expert Opin Biol Ther· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progress in the pharmacotherapy of uveitis: the art of personalized care.
Shivam H Patel, Aditya Belamkar, Amir R Hajrasouliha, Denis Jusufbegovic, Thomas A Ciulla

Expert Opin Pharmacother· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration.
Stephen H Poor, Georges Weissgerber, Christopher M Adams, Harit Bhatt, David J Browning, Thomas A Ciulla

Am J Ophthalmol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Genetic Mechanisms in Age-Related Macular Degeneration.
Aumer Shughoury, Duriye Damla Sevgi, Thomas A Ciulla

Genes (Basel)· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optical Coherence Tomography Anatomic and Temporal Biomarkers in Uveitic Macular Edema.
Thomas A Ciulla, Barry Kapik, Mark R Barakat, Rahul N Khurana, Quan Dong Nguyen

Am J Ophthalmol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suprachoroidal triamcinolone acetonide versus rescue therapies for the treatment of uveitic macular oedema: A post hoc analysis of PEACHTREE.
Michael A Singer, Pauline Merrill, Steven Yeh, Colette Hall, Barry Kapik, Thomas A Ciulla

Clin Exp Ophthalmol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease progression pathways of wet AMD: opportunities for new target discovery.
Amber T Wolf, Alon Harris, Francesco Oddone, Brent Siesky, Alice Verticchio Vercellin, Thomas A Ciulla

Expert Opin Ther Targets· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis